Cytokeratin 5/6(CK5/6), also known as Keratin 5/6, is a type of intermediate filament protein which is typically expressed in basal cells of various epithelial tissues, such as the skin, respiratory tract, and breast. In the breast, it is mainly found in the myoepithelial cells that surround the ducts and lobules. It has important values in the diagnosis, treatment, and prognosis evaluation of breast cancer.

In 2000, F. Otterbach et al. found out that CK 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations from benign lesions of the breast¹. After 3 years, Magali Lacroix-Triki et al. pointed out that CK 5/6 was strongly expressed in usual ductal hyperplasia². In 2009, TAKUYA MORIYA et al. showed that CK 5/6 could be used to distinguish between low-grade ductal carcinoma in situ and benign lesions³.

CK 5/6 is also very useful in the diagnosis of identifying more fatal breast cancers. In 2006, Chad A. Livasy et al. found out the existence of CK 5/6 staining in basal-like subtype of breast ductal carcinoma in situ⁴. In 2010, Amarpreet Bhalla et al. pointed out that CK 5/6 was expressed not only in benign but also in malignant breast lesions⁵. The above studies indicated that CK 5/6 was a marker of basal-like ductal carcinoma in situ of breast.

In the past decade, due to progress of companion diagnostics and targeted drug therapies, CK 5/6 has begun to be applied in research of medication and prognosis of triple-negative breast cancer.

In 2014, high c-Met and CK 5/6 expressions, and PTEN loss were found to increase risk of recurrence and death in patients with triple-negative breast cancer⁶. In 2017, Aziza E. et al. pointed out that EGFR and CK 5/6 were adverse prognostic markers in TNBC. EGFR and CK 5/6 expression could serve as biomarkers for identifying TNBC patients with poor survival that were unlikely to benefit from neo adjuvant chemotherapy⁷. Later, other study revealed that CK 5/6 and EGFR are biomarkers for TNBC prognosis⁸.

The rabbit monoclonal antibody against CK 5/6 from Dartmon shows excellent staining results, whether it is for the usual ductal hyperplasia (UDH) tissue, atypical ductal hyperplasia (ADH), or ductal carcinoma in situ (DCIS) tissue. It meets your staining expectations and helps in the diagnosis of breast cancer.

Why choose Dartmon:

• CE and FDA approved antibody
• Ready-to-use and concentrated antibody
• Compatible with manual and automated systems

Ordering Information

Product name: Anti- Cytokeratin 5/6 (DA045)

Cat. No. : RMB1A014

Usage pattern: Manual or device utilization

Ready-to-use: 3ml, 6ml, 10ml

Concentrated: 0.1ml, 0.5 ml, 1ml